Why the study?
Do established and emerging biomarkers improve cardiovascular risk prediction beyond standard European risk scores in primary and secondary prevention cohorts?
Do established and emerging biomarkers improve cardiovascular risk prediction beyond standard European risk scores in primary and secondary prevention cohorts?
The BiomarCaRE project outlines the rationale and design for assessing established and emerging biomarkers for cardiovascular risk prediction in over 300,000 European participants.
No takes yet. Share an insight, caveat, or question.
BiomarCaRE design enables large-scale biomarker testing in Europeans; leaves open added value beyond standard risk scores.
Zeller et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: